WSJ: There is more to medicine than randomized controlled trials
Writing for the Wall Street Journal’s opinion page, Allysia Finley explains that while randomized controlled trials can yield important insights, it is a medical mistake and a disservice to patients to dismiss other types of evidence. Very relevant in the context of COVID-19 treatments, especially hydroxychloroquine.
“Some experts have dismissed the antimalarial hydroxychloroquine, or HCQ, even though more than a dozen observational studies have found it beneficial. A retrospective observational study of Covid-infected nursing-home residents in France, for instance, found those treated with HCQ and azithromycin were 40% less likely to die.”
Read the whole thing here.